Which medications increase the risk of unilateral breast swelling and pain (gynecomastia) in older men?

Medications That Increase Risk of Gynecomastia in Older Men

Spironolactone is the most important medication to recognize as causing gynecomastia in older men, with rates of 10% at low doses (25 mg/day) and up to 52% at higher doses (≥150 mg/day). 1

Primary Culprit Medications

Spironolactone (Highest Risk)

• Dose-dependent gynecomastia risk: 10% at 25 mg/day, escalating to 52% at doses ≥150 mg/day 1
• Mechanism: Non-selective mineralocorticoid receptor antagonist with anti-androgenic effects
• Can present as unilateral or bilateral breast swelling and pain 2
• Clinical pearl: When prescribing spironolactone to older men, consider eplerenone as an alternative, which lacks anti-androgenic side effects and does not cause gynecomastia 1
• Symptoms typically improve within 1 month of discontinuation 2

5-Alpha Reductase Inhibitors (Moderate-High Risk)

• Finasteride and dutasteride for benign prostatic hyperplasia significantly increase gynecomastia risk (IRR=3.55, OR=3.31) 3
• Dutasteride carries higher risk than finasteride 3
• Risk persists regardless of prescription duration or concomitant medications 3

Androgen Receptor Pathway Inhibitors (High Risk with Monotherapy)

• Enzalutamide, darolutamide, and apalutamide as monotherapy increase gynecomastia risk 5-fold (RR: 5.19) compared to ADT alone 4
• Important distinction: When combined with ADT, these agents do NOT significantly increase gynecomastia risk (RR: 1.27, p=0.2) 4

Secondary Medications to Consider

Statins (Modest Risk)

• Increased risk with current use (RR: 1.19), recent use (RR: 1.38), and past use (RR: 1.20) 5
• Mechanism: May decrease circulating testosterone levels
• Risk applies to men over and under 50 years old 5

Proton Pump Inhibitors (Modest Risk)

• Adjusted HR of 1.30-1.48 for gynecomastia development 6
• Risk elevated in both younger (≤50 years: HR 1.32) and older men (>50 years: HR 1.48) 6

DPP-4 Inhibitors (Emerging Risk)

• Sitagliptin shows strongest signal (ROR: 2.37-4.84) 7
• Vildagliptin also associated (ROR: 3.34) 7
• Particularly relevant in older diabetic men with already-lowered androgen levels 7

Other Cardiac Medications

• Digoxin (mentioned in heart failure guidelines) 8, 9
• H2 receptor antagonists (H2 blockers) 5

Clinical Algorithm for Evaluation

When an older man presents with unilateral or bilateral breast swelling/pain:

1. Medication review priority order:

   • First: Check for spironolactone, 5-ARIs, or ARPI monotherapy
   • Second: Review statins, PPIs, DPP-4 inhibitors
   • Third: Assess ketoconazole, risperidone, testosterone replacement 5, 6

2. Distinguish drug-induced from pathologic causes:

   • Drug-induced typically improves within 1 month of discontinuation 2
   • Unilateral presentation does NOT exclude drug etiology 2
   • Consider breast cancer in older men (median age 63) with associated symptoms (nipple discharge, skin retraction, fixed mass) 10

3. Management approach:

   • For spironolactone: Switch to eplerenone (lacks anti-androgenic effects) 1
   • For 5-ARIs: Consider switching to alpha-blockers alone if BPH symptoms allow 3
   • For ARPI monotherapy: Add ADT to eliminate excess gynecomastia risk 4
   • For bicalutamide: Prophylactic tamoxifen or radiotherapy effectively prevents gynecomastia 4

Critical Pitfalls to Avoid

• Don't assume bilateral presentation: Drug-induced gynecomastia can be unilateral 2
• Don't overlook medication history: Drug-induced gynecomastia accounts for approximately 25% of all cases 2
• Don't delay cancer evaluation: 50% of men with breast cancer have coexisting gynecomastia, though gynecomastia itself is not a cancer risk factor 10
• Don't continue spironolactone unnecessarily: Eplerenone is equally effective at 2-3x the dose without causing gynecomastia 1